Untitled

Besch, Dorothea; Kurtenbach, Anne; Apfelstedt-Sylla, Eckart; Sadowski, Bettina; Dennig, Dieter; Asenbauer, C.; Zrenner, Eberhart; Schiefer, Ulrich

doi:10.1023/a:1014644307518

Cited by 60 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also indications of the presence of GABA receptors on photoreceptors and horizontal cells. In the present study, OPs were decreased in both high-dose and low-dose rabbits, reflecting disturbances in inner retinal function, in accordance with several clinical studies revealing OP alterations [11,13,18,19,23,[25][26][27][28]. b-wave amplitudes derived from the isolated cone responses both in rabbits [37,38] and humans [16,49], a well-known phenomenon in VGB treatment [11, 13, 16, 18-20, 22-25, 49],which also has been described in rats [39].…”

Section: Discussionsupporting

confidence: 92%

“…The cause of the visual field defects is still not fully understood. Numerous studies have revealed alterations of full-field ERG (ff-ERG) responses [11,13,16,[18][19][20][21][22][23][24][25][26][27][28], suggesting retinal damage as the origin of visual field defects. VGB medication has been correlated to a reduction of rod b-wave amplitudes and cone b-wave amplitudes, as well as to a decline of amplitudes of oscillatory potentials (OPs), reflecting inner retinal function.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication

Kjellström

Bruun

Ghosh

et al. 2009

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

In this study, VGB medication was associated, in a dose-related manner, with a decrease of ff-ERG amplitudes as well as with altered protein expression in rod bipolar cells and Müller cells, suggesting alterations of inner retinal function. The dose-related morphological and electrophysiological changes indicate a retinal pathology that may explain the constricted visual fields seen in some patients treated with VGB.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication

Kjellström

Bruun

Ghosh

et al. 2009

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In some patients, the abnormalities in mfERG amplitudes appeared to correspond well with VF defects [43,47], whereas in other patients the abnormalities may be more diffuse than VF findings [43] or have a poor correlation [42,45]. Besch et al [48] observed delayed multifocal oscillatory potentials in patients taking VGB with marked VF defects but without visual complaints and with normal visual acuity, color vision and dark adaptation thresholds. This finding indicates that VGB-related VF defects may be a result of inner retinal dysfunction.…”

Section: Vgb Retinopathymentioning

confidence: 99%

The Role of Multifocal Electroretinography in the Assessment of Drug-Induced Retinopathy: A Review of the Literature

Dettoraki

Moschos²

2016

Ophthalmic Res

View full text Add to dashboard Cite

Multifocal electroretinography (mfERG) is an objective, noninvasive examination for the assessment of visual function. It enables the stimulation of multiple retinal areas simultaneously and recording of each response independently, providing a topographic measure of retinal electrophysiological activity in the central 40-50° of the retina. A clinical application of mfERG represents the assessment of retinal toxicity associated with systemic medications. Drug-induced retinopathy represents a disease that, although not common, requires early recognition: if not detected early, it may progress and cause irreversible retinal dysfunction with subsequent visual impairment. This review aims to evaluate the use of mfERG in the assessment of retinal dysfunction associated with various systemic pharmacological agents based on the currently available literature. The most commonly recognized systemic medications affecting retinal function are included, such as chloroquine and hydroxychloroquine, vigabatrin, deferoxamine, ethambutol, interferon-α, tamoxifen, digoxin, sildenafil, canthaxanthin, amiodarone and nefazodone. The role of mfERG in the early diagnosis of retinal toxicity and the evaluation of disease severity is reviewed, as well as its clinical value in monitoring disease progression or recovery after drug cessation.

show abstract

Retinal Function Abnormalities in Patients Treated With Vigabatrin

Banin

Shalev²,

Obolensky³

et al. 2003

Arch Ophthalmol

View full text Add to dashboard Cite

Objective: To evaluate central and peripheral retinal function in patients treated with vigabatrin, an antiepileptic drug associated with peripheral visual field constriction (VFC). Methods: Six patients with epilepsy treated with vigabatrin as add-on therapy for at least 3 years were included in this observational case series. All patients underwent a clinical ophthalmologic examination, color vision testing, standard perimetry, and full-field and focal foveal cone electroretinography. Four patients, 3 of whom had VFC, completed specialized computerized static light-and dark-adapted perimetry.

show abstract

Untitled

Abstract: The present data indicate an effect of vigabatrin on the inner retinal layers. Since abnormalities of the oscillatory potentials were seen in all patients with visual field defects a dysfunction of GABA-ergic retinal cell transmission might be assumed.

Cited by 60 publications

References 29 publications

Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication

Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication

The Role of Multifocal Electroretinography in the Assessment of Drug-Induced Retinopathy: A Review of the Literature

Retinal Function Abnormalities in Patients Treated With Vigabatrin

Contact Info

Product

Resources

About